viewRedx Pharma PLC

Redx Pharma secures short-term funding; assessing longer-term solutions

A loan of up to £2.5mln is being provided by 18.6% shareholder Moulton Goodies

scientist filling sample tray
In the meantime work continues: Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year

Redx Pharma (LON:REDX) has secured short-term funding with a loan of up to £2.5mln and is in talks to find a longer-term financing solution.

Shareholder Moulton Goodies Ltd has agreed to provide the secured loan note facility, with £1mln being drawn down immediately. The coupon is 10% a year and there is an option to turn the debt into equity in certain circumstances.

At the same time boss Lisa Anson and her executive team remain in “active discussions” with shareholders and “third-party healthcare specialist investors” to find a more sustainable and efficient method of bankrolling the group.

Value realisation 

Investors were told Redx is also looking to “pursue potential value realisation opportunities” for its pan-RAF cancer research programme. 

“The company will provide further updates in due course,” the firm added.

The loan runs until the end of the year and can be capitalised in the event of an equity fundraiser of at least £10mln (though there are provisions to turn the debt into shares at a lesser amount). Moulton, which owns 18.6% of Redx, would receive new shares at a discount to the price they are offered.

As the lender owns such a large chunk of the business it is being treated as what’s called a related-party transaction under AIM’s rules. Therefore, Redx took advice before agreeing the financing deal.

“The board consider that the terms of the loan are fair and reasonable insofar as the company's shareholders are concerned, having consulted with Cantor Fitzgerald Europe, the company's nominated adviser,” shareholders were told.

Results update

In a separate update, Redx published financial results for the six months to the end of March, which showed the company had £3.3mln in the bank at that point, although operating expenses for the period were £5mln.

Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year, with the full read-out expected in early 2020.

Currently one patient has received a first cycle of treatment with two joining the first group soon. Redx believes the “required exposures” to the drug will be in the 0.5-3mg range.

Quick facts: Redx Pharma PLC

Price: 57.5 GBX

Market: AIM
Market Cap: £112.27 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma PLC named herein, including the promotion by the Company of Redx Pharma PLC in any Content on the Site, the Company receives from...


Redx Pharma PLC in a great place to move forward after Astra deal says CEO

Lisa Anson, chief executive of Redx Pharma PLC (LON:REDX) says the out-license deal with AstraZeneca for its fibrosis porcupine inhibitor is good news for the company and also for people suffering from the condition. Using a porcupine inhibitor in lung-scarring diseases such as IPF is a novel...

on 4/8/20

2 min read